Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Assessment of The Effect of Tocilizumab in Adult Hospitalized COVID-19 Pneumonia Patients: A Clinical Trial

View through CrossRef
ackground: Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disease causing potentially severe acute respiratory infection which may lead to multi-organ dysfunction or failure due to severe acute respiratory syndrome coronavirus (SARS-CoV-2) also known as novel coronavirus (nCoV). Tocilizumab is anti-interleukin-6 receptor antibody may have potential role in minimizing mortality and mechanical ventilation requirements among hospitalized COVID-19 patients. Objective: To analyze the effect of tocilizumab in adult hospitalized COVID-19 pneumonia patients. Methods: This non-randomized, controlled, open-label trial was carried out at a tertiary care hospital, Sylhet, Bangladesh. Hospitalized COVID-19 pneumonia patients with hypoxia ( oxygen saturation < 92% on air or required oxygen) and proof of systemic inflammation(C-reactive protein ≥50mg/L) were assigned (in 1:1 ratio) to receive a standard care plus single dose of tocilizumab (8mg/kg up to a maximum of 800mg) or only standard care, who were not provided mechanical ventilation. Primary outcomes were 28-day mortality and necessity of mechanical ventilation. Results: The mean age was 59.08±12.39 years in tocilizumab group and mean age was 55.41±12.82 years in control group. Maximum patients were >60 years. The most common symptoms were fever (44.4%) then cough (38.9%), and others including diarrhoea, fatigue (33.3%). Majority risk factors were DM (47.7%) followed by HTN (30.5%). Mortality was more in control group than tocilizumab group which was 83.3% and 44.4% respectively. It is also observed that tocilizumab group patients needed mechanical ventilation significantly lower than the control group which was 19.4% and 44.4% respectively. The difference was statistically remarkable between the two groups (P<0.05). Conclusion: This study shows that hospitalized COVID-19 patients who were not receiving mechanical ventilation,tocilizumab increased survival rate and reduced the need of mechanical ventilation.
Title: Assessment of The Effect of Tocilizumab in Adult Hospitalized COVID-19 Pneumonia Patients: A Clinical Trial
Description:
ackground: Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disease causing potentially severe acute respiratory infection which may lead to multi-organ dysfunction or failure due to severe acute respiratory syndrome coronavirus (SARS-CoV-2) also known as novel coronavirus (nCoV).
Tocilizumab is anti-interleukin-6 receptor antibody may have potential role in minimizing mortality and mechanical ventilation requirements among hospitalized COVID-19 patients.
Objective: To analyze the effect of tocilizumab in adult hospitalized COVID-19 pneumonia patients.
Methods: This non-randomized, controlled, open-label trial was carried out at a tertiary care hospital, Sylhet, Bangladesh.
Hospitalized COVID-19 pneumonia patients with hypoxia ( oxygen saturation < 92% on air or required oxygen) and proof of systemic inflammation(C-reactive protein ≥50mg/L) were assigned (in 1:1 ratio) to receive a standard care plus single dose of tocilizumab (8mg/kg up to a maximum of 800mg) or only standard care, who were not provided mechanical ventilation.
Primary outcomes were 28-day mortality and necessity of mechanical ventilation.
Results: The mean age was 59.
08±12.
39 years in tocilizumab group and mean age was 55.
41±12.
82 years in control group.
Maximum patients were >60 years.
The most common symptoms were fever (44.
4%) then cough (38.
9%), and others including diarrhoea, fatigue (33.
3%).
Majority risk factors were DM (47.
7%) followed by HTN (30.
5%).
Mortality was more in control group than tocilizumab group which was 83.
3% and 44.
4% respectively.
It is also observed that tocilizumab group patients needed mechanical ventilation significantly lower than the control group which was 19.
4% and 44.
4% respectively.
The difference was statistically remarkable between the two groups (P<0.
05).
Conclusion: This study shows that hospitalized COVID-19 patients who were not receiving mechanical ventilation,tocilizumab increased survival rate and reduced the need of mechanical ventilation.

Related Results

Tocilizumab May Be a Key in Therapy for Cytokine Release Syndrome in Older Patients With Severe Symptoms of COVID-19
Tocilizumab May Be a Key in Therapy for Cytokine Release Syndrome in Older Patients With Severe Symptoms of COVID-19
Abstract Background Older adults are more susceptible to the novel coronavirus disease 2019 (hereafter, COVID-19) and more likely to develop severe illness. Cytokine releas...
Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study
Factors Influencing Disease Stability and Response to Tocilizumab Therapy in Severe COVID-19: A Retrospective Cohort Study
(1) Background: The efficacy of tocilizumab in COVID-19 has been doubted. The study aimed to investigate factors affecting disease stability and response to tocilizumab among sever...
THE ROLE OF TOCILIZUMAB IN TREATMENT OF COVID-19
THE ROLE OF TOCILIZUMAB IN TREATMENT OF COVID-19
Introduction and Aim: COVID-19, especially severe in the elderly, causes symptoms ranging from mild to critical organ failure and death. Treatments have included chloroquine, hydro...
International Breast Cancer Study Group (IBCSG)
International Breast Cancer Study Group (IBCSG)
This section provides current contact details and a summary of recent or ongoing clinical trials being coordinated by International Breast Cancer Study Group (IBCSG). Clinical tria...
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
Tocilizumab Effect in COVID-19 Hospitalized Patients: A Systematic Review and Meta-Analysis of Randomized Control Trials
AbstractSince the emergence of the first cases of COVID-19 viral pneumonia late 2019 several studies evaluated the benefits of different treatment modalities. Early in the pandemic...
Electrocardiographic markers of increased risk of sudden cardiac death in patients with COVID‐19 pneumonia
Electrocardiographic markers of increased risk of sudden cardiac death in patients with COVID‐19 pneumonia
AbstractBackgroundLittle is known about the role of ECG markers of increased risk of sudden cardiac death during the acute period of coronavirus disease 2019 ( COVID‐19) pneumonia....

Back to Top